Lipase Reagent Market size was valued at USD 721.08 billion in 2024 and is likely to cross USD 1.71 trillion by 2037, expanding at more than 6.9% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of lipase reagent is estimated at USD 802.88 billion.
The growth of the market can be attributed to the increasing number of patients who are suffering from different diseases that require lipase analysis. The lipase testing reagents act as indicators to study the presence of pancreas-related disorders and other gastric problems. The rise in widespread demand for lipase testing reagents on account of indigestion, acute and chronic pancreatic disorders, gastroesophageal reflux disease (GERD). and other intestinal disorders is expected to drive the market growth during the forecast period. The incidence of acute pancreatitis raised from 28 per 100,000 population in 1999 to 36 per 100,000 population in 2010.
In addition to these, factors that are believed to fuel the market growth of Lipase Reagent include the increase in diseases like vitamin deficiency, dehydration, malnutrition, high gastric acids, and persistent diarrhea. As per the Centers for Disease Control and Prevention, the number of adults diagnosed with ulcers was about 14.8 million in 2018.
Besides, the demand for lipase testing reagents market is propelling as children with cystic fibrosis (CF) or Schwachman-Diamond Syndrome (SDS) diagnosis increase. Lipase levels are high in patients with cystic fibrosis. According to the World Gastroenterology Organization, out of 100%, 49% of females and 36.6% of males have the most common disorders like constipation, diarrhea, IBS, proctalgia fungal, and dyspepsia at rates of 11.7%, 4.7%, 4.1%, 5.9%, and 7.2% respectively.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.9% |
|
Base Year Market Size (2024) |
USD 721.08 billion |
|
Forecast Year Market Size (2037) |
USD 1.71 trillion |
|
Regional Scope |
|
Application (Hospitals, Clinics)
The global lipase reagent market is segmented and analyzed for demand and supply by application into hospitals, clinics & others, out of which, the hospital segment is anticipated to hold the largest market size by the end of 2037. The market is estimated to grow on account of expanding healthcare sector and advancements in technology within the medical sector for diagnostics and therapeutics. As per estimations of the Organization for Economic Co-operation and Development (OECD), health expenditure raised by 5% from 8.8% GDP in 2019 to 9.7% GDP in 2020 across OECD countries.
Indication (Pancreatic Disorders, Cancer, Cystic Fibrosis)
The global lipase reagent market is also segmented and analyzed for demand and supply by indication into pancreatic disorders, cancer, and cystic fibrosis. Out of these segments, the pancreatic disorders segment is projected to garner the highest market revenue by the end of 2037. The segment is growing on the fact that most cases of high lipase levels indicate a problem with the pancreas. For pancreatic illnesses to be effectively treated and managed, an accurate and fast diagnosis is essential, and measuring lipase levels can be a key step in this process. For instance, it was found that about 45 to 350 in million people suffer from acute pancreatitis in the U.S.
Our in-depth analysis of the global market includes the following segments:
|
By Type |
|
|
By Application |
|
|
By Indication |
|
North American Market Forecast
North America industry is set to hold largest revenue share of 36% by 2037, on the back of increasing concern among people about complications related to the gastrointestinal tract. Among 440 million non-cancer medical conditions, over 22 million acute digestive conditions with 11 million gastroenteritis and 6 million indigestion cases are reported. Besides, the North American region is having good infrastructure and more hospitals propelling the growth of the global lipase reagent market during the forecast period. According to the American Hospital Association, the total number of all hospitals in the North American region is 6,000 with staffed beds of 920,000 in 2022. Also, the regional government policies towards public health care programs attribute to the growth of the market.
APAC Market Statistics
Moreover, the Asia Pacific lipase reagent market is also growing at a fast rate, owing to the rising demand for lipase reagents in the pharma, food and beverage, and biotech sectors. The need for lipase reagents for use in developing drugs, biomarker identification, and bioprocessing applications is rising as a result of the rapidly developing biotechnology and pharmaceutical sectors. The requirement for lipase reagents in the detection and treatment of lifestyle-related disorders like diabetes and obesity is rising as their prevalence rises. The need for lipase reagents for use in food evaluation and quality control is also rising as a result of the region's expanding food and beverage industries, notably in nations like China and India.
AzuR: announced a positive result of MS1819 during phase 2 trials, by assessing MS1819 along with porcine-derived pancreatic enzyme replacement therapy for treating severe exocrine pancreatic insufficiency in patients with cystic fibrosis.
DiaSysDiagnostic Systems GmH announced the development of Lipase DC FS, a state-of-the-art direct colorimetric assay, with improved stability for Pancreatic Diagnosis.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?